

STAAR SURGICAL CO  
Form 8-K  
October 22, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 22, 2004

**STAAR SURGICAL COMPANY**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	0-11634 (Commission File Number)	95-3797439 (I.R.S. Employer Identification No.)
---	-------------------------------------	--

1911 Walker Avenue, Monrovia, California  
(Address of principal executive offices)

91016  
(Zip Code)

(626) 303-7902  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

SIGNATURES

---

**Table of Contents**

**Item 8.01. Other Events.**

As previously announced on September 29, 2004, the United States Food and Drug Administration (the FDA ) completed the inspection of the Company s Monrovia facility on September 23, 2004 and issued a form FDA 483 Inspectional Observations (the FDA 483 ). The Company intends to respond to the FDA 483 on November 4, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STAAR SURGICAL COMPANY

Date: October 22, 2004

By: /s/ John Bily  
John Bily,  
Chief Financial Officer

- 2 -